Immunome, Inc. Company Analysis & Research
Immunome, Inc., a clinical-stage biotechnology company, develops targeted cancer therapies. The company is advancing an innovative portfolio of therapeutics, drawing on leadership that previously played key roles in the design, development, and commercialization of cutting-edge targeted cancer therapies, including antibody-drug conjugate therapies (ADCs). With recent Phase 3 positive results and expanding pipeline, Immunome is positioned as a promising oncology-focused biotech targeting multiple cancer indications.
Immunome is a clinical-stage biotechnology company focused on discovering and developing first-in-class targeted therapies for oncology, primarily using antibody-drug conjugate (ADC) technology, leveraging a proprietary, memory B cell-based discovery engine to identify novel antibodies that treat cancers. The company's strategy is centered on cell-surface-targeting agents and small molecules, with the ultimate goal to develop a targeted oncology platform that can overcome resistance and enable bystander activity.
Company Overview
Founded: 2006. Headquarters: Bothell, Washington. Market Cap: $2.45B. Ticker: IMNM (NASDAQ).
Industry
Biopharmaceuticals - Targeted Oncology/Immunotherapy
Cyborg Score: 6/10 — Solid
Immunome represents a clinical-stage oncology platform with validated Phase 3 data and multi-asset portfolio pursuing high-value cancer indications, though success depends on regulatory approvals and clinical advancement.
The company delivered top-line Phase 3 results for Varegacestat in desmoid tumors and is in the process of filing a New Drug Application as it sets its sights on a $1 billion market opportunity. However, as a clinical-stage biotech, the company remains pre-commercial with significant development risk, balanced by a validated pipeline approach and recent regulatory progress.
Key Strategic Insights for Immunome, Inc.
- Phase 3 positive results for Varegacestat in desmoid tumors with NDA filing underway, targeting a $1 billion market opportunity and plans to submit three additional INDs this year for solid tumor programs.
- Company's radioligand therapy (IM-3050) receives FDA clearance and is poised to start clinical trials.
- Advanced pipeline includes Varegacestat in Phase 3 for desmoid tumors and IM-1021 (ROR1-ADC) in Phase 1, with preclinical solid tumor ADC candidates in development.
- Current market capitalization of $2.45B as of latest update.
Recent Developments
- (February 2026) Immunome grants 30,000 inducement stock options to new employee at $26.14 exercise price
- (December 2025) Announced positive topline Phase 3 results from RINGSIDE trial of Varegacestat in desmoid tumors
- (December 2025) Completed public offering of common stock
- (February 2026) CEO Clay Siegall reiterates focus on building oncology-focused pipeline with expanded strategic initiatives
Competitors & Competitive Landscape
- Various (Gilead, Seagen, Pfizer, others) — Established ADC developers with marketed or late-stage programs
- Various oncology companies — Companies developing alternative desmoid tumor and cancer therapeutics
- Novartis, Bayer, others — Competitors in targeted radiation therapy space
Immunome competes in the targeted oncology and ADC therapeutics space against established biotech and pharma competitors developing cancer therapies. Key competitive differentiators include the company's proprietary memory B cell-based discovery engine, validated Phase 3 clinical data, and multi-asset pipeline focusing on cell-surface-targeting and radiotherapy approaches.
More Company Research
TELA Bio, Inc. Westwater Resources, Inc. Bergbahnen Engelberg-Trübsee-Titlis AG Hellenic Exchanges - Athens Stock Exchange S.A. ECN Capital Corp. Tata Teleservices (Maharashtra) Limited Tabcorp Holdings Limited Sun Art Retail Group Limited Kodiak Gas Services, Inc. TC Energy Corporation Beazley plc CCL Industries Inc. Lundin Mining Corporation Nasdaq, Inc. Playgon Games Inc.Full Company Research Reports
Looking for a more in-depth analysis of Immunome, Inc.? AskCyborg's Company Research section contains full AI-generated reports with detailed financials, strategic analysis, and Cyborg Score ratings. Browse the complete company research library or explore industry research reports.
AskCyborg provides AI-powered company research and analysis. Visit AskCyborg for full reports, Cyborg Score ratings, and analyst podcasts.